CDT Equity (NASDAQ:CDT) vs. Fractyl Health (NASDAQ:GUTS) Head to Head Comparison

CDT Equity (NASDAQ:CDT) and Fractyl Health (NASDAQ:GUTS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Valuation and Earnings

This table compares CDT Equity and Fractyl Health”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22 million	($66,338.55)	0.00
Fractyl Health	$90,000.00	1,330.37	-$140.95 million	($1.84)	-0.41

CDT Equity has higher earnings, but lower revenue than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for CDT Equity and Fractyl Health, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1	0	0	0	1.00
Fractyl Health	1	1	3	0	2.40

Fractyl Health has a consensus target price of $5.40, suggesting a potential upside of 615.52%. Given Fractyl Health’s stronger consensus rating and higher probable upside, analysts plainly believe Fractyl Health is more favorable than CDT Equity.

Volatility and Risk

CDT Equity has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. Comparatively, Fractyl Health has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500.

Insider and Institutional Ownership

3.3% of CDT Equity shares are owned by institutional investors. 10.8% of CDT Equity shares are owned by insiders. Comparatively, 8.5% of Fractyl Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares CDT Equity and Fractyl Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-4,263.33%	-529.91%
Fractyl Health	N/A	-2,896.77%	-104.24%

Summary

Fractyl Health beats CDT Equity on 8 of the 12 factors compared between the two stocks.

About CDT Equity

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

About Fractyl Health

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.